VAL-083 is primarily used in the field of oncology as a potential treatment for various types of cancer, particularly glioblastoma multiforme (GBM), an aggressive form of brain cancer. It functions as a DNA-targeting agent, causing interstrand cross-links that disrupt DNA replication and transcription, ultimately leading to cancer cell death. Its ability to bypass mechanisms of drug resistance, such as MGMT-mediated repair, makes it a promising therapeutic option for tumors that are resistant to standard treatments like temozolomide. VAL-083 is currently under clinical investigation to evaluate its efficacy and safety in treating recurrent or refractory GBM and other solid tumors. Additionally, its potential application in treating hematologic malignancies, such as acute myeloid leukemia (AML), is being explored, highlighting its versatility in cancer therapy.